Nisarat OpartkiattikulSathien SukpanichnantWanchai WanachiwanawinSuthat FucharoenYoshinori FunaharaAkinobu SumiyoshiKiyohiro ImaiWanida SangtawesinPanutsaya ThientadakulMahidol UniversityKobe University School of MedicineUniversity of MiyazakiOsaka University2018-07-042018-07-041997-12-01Southeast Asian Journal of Tropical Medicine and Public Health. Vol.28, (1997), 167-171012515622-s2.0-0031306251https://repository.li.mahidol.ac.th/handle/20.500.14594/18043Since the obtained results from the pilot study indicated that dilazep which was a membrane stabilizer would be benefit to treatment and prevention of anemia and chronic leg ulcer in β-thalassemia/hemoglobin E (β-thal/HbE) patients, the authors had continued the study in a second phase, ie a double blind placebo control trial. Twenty-seven β-thal/HbE patients were recruited in the study. Eight patients who suffered from chronic leg ulcer were given dilazep. The rest of patients were given dilazep or placebo according to a randomized table. Hence, 16 patients received dilazep and 11 received placebo. When we compared the number of unit of blood transfusion, hemoglobin level, 2-3 DPG and P50 value between the dilazep and placebo groups using unpaired t-test, we found that there were no statistical differences in any of the parameters. However, when we compared the data within the group using paired t-test, there was statistical decrease in blood requirement after treatment in the dilazep group (p<0.05). Concerning with the treatment of chronic leg ulcer. 3 in 8 patients were completely healed within 3 months. 4 in 8 patients were improved and 1 in 8 patients was not improved There were complaints of skin itching and mild epigastric pain in placebo group but the liver function tests, kidney function tests and cardiac enzyme did not significantly change during the medication.Mahidol UniversityMedicineArticleSCOPUS